

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 17-4-2008

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 08-3-2008 TO BE PUBLISHED ON 18-4-2008 IN  
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

225/2008	<b><u>03-03-2008</u></b> The Regents of the University of Colorado. USA. (Priority 09-03-07 USA)	“Synthesis of zeolites and zeolite membranes using multiple structure directing agents”
226/2008	<b><u>04-03-2008</u></b> Teijin Pharma Limited Japan. (Priority 06-3-07 Japan)	“1-Biarylazetidione derivative”
227/2008	Plexxikon, Inc. USA. (Priority 08-3-07 USA)	“Ppar active compounds”
228/2008	Nestec S.A. Switzerland. (Priority 09-3-07 USA)	“Hygienic baking pan and methods for producing and using same”
229/2008	Bristol-Myers Squibb Company. USA. (Priority 14-3-07 USA)	“Compounds for the treatment of hepatitis C”
230/2008	<b><u>05-03-2008</u></b> Honda Motor Co., Ltd. Japan. (Priority 29-3-07 Japan)	“vehicle fuel supply device and fuel filter structure”
231/2008	TransForm Pharmaceuticals, Inc. USA. (Priority 05-3-07 USA)	“Polymorphs of 7-[(3-chloro-6,11-dihydro- 6-methyldibenzo[C,F][1,2] thiazepin-11- yl)amino]heptanoic acid S,S dioxide and methods of making and using the same”
232/2008	Glaxo Group Limited. United Kingdom. (Priority 07-3-07 GB)	“Compound”
233/2008	<b><u>06-03-2007</u></b> Wyeth. USA (Priority 06-03-2007 USA)	“Sulfonylated heterocycles useful for modulation of the progesterone receptor”

234/2008	Wyeth. USA (Priority 06-03-2007 USA)	“aryl sulfonamides useful for modulation of the progesterone receptor”
	<b>07-03-2008</b>	
235/2008	1. Syngenta Participations AG (Switzerland) 2. Syngenta Limited. United Kingdom. (Priority 09-03-07 U.K)	“Novel herbicides”
236/2008	1. Syngenta Participations AG (Switzerland) 2. Syngenta Limited. (United Kingdom) (Priority 09-3-07 U.K)	“Novel Herbicides”
237/2008	Wyeth. USA. (Priority 09-3-07 USA)	“synthesis and characterization of polymorph form III of 4-(2-(4,4-Dimethyl-2-Oxooxazolidin-3-yl)thiazol-4-yl)benzotrile”
238/2008	Wyeth. USA. (Priority 09-3-07 USA)	“Synthesis and characterization of polymorph form II of 4-(2-(4,4-Dimethyl-2-Oxooxazolidin-3-yl)thiazol-4-yl)benzotrile”
239/2008	Novartis AG. Switzerland. (Priority 09-3-07 USA)	“Treatment of melanoma”
240/2008	Otsuka Pharmaceutical Co. Ltd. Japan. (Priority 09-3-07 Japan)	“A medicament for treating chronic obstructive pulmonary disease”
241/2008	Sanofi-Aventis. France. (Priority 09-3-07 USA)	“Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof”
	<b>08-03-2008</b>	
242/2008	Cracol Developments Ltd. Cyprus (Priority 10-3-07 GB)	“A device”

243/2008	Otsuka Pharmaceutical Co. Ltd. Japan. (Priority 09-3-07 Japan)	“Freeze-dried preparation containing influenza vaccine and method for producing the same”
244/2008	Omya Development AG. Switzerland. (Priority 21-3-07 EP)	“Process for the removal of endocrine disrupting compounds”

XXXXXXXXXXXX

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


452/1996	Warner-Lambert Company. USA.	“Form III crystalline [R- (R*, R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)”  (C07D 207/38, 209/60)	139452
		A novel crystalline form of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form III is characterized by its X-ray powder diffraction and/or solid state NMR is described, and pharmaceutical composition of the same, which is useful as an agent for treating hyperlipidemia and hypercholesterolemia.	
760/1996	Pfizer Inc. USA	“Compound of 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine”  (INT: CL, C07D 211/06, 295/04)	139453
		<b>(ABANDONED)</b>	

79/1998 Dimminaco AG. Switzerland. “Infectious bursitis vaccine”  
 (INT: CL, C12N 7/08, A6IK 39/12)  
 139454  
 The present invention is concerned with a vaccine which is capable of protecting poultry against infectious Bursitis Infections, characterized in that it contains an infectious bursitis virus which has the combined properties of upon administration to a chicken causing a reduction in the size of the bursal size, expressed as bursa/body weight ratio, of less than 55% and the capability to protect poultry having an ELISA antibody titer of at least about 500 and with viruses having the above characteristics.

825/1998 Pfizer Products Inc. USA. “Solid dispersion comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS)”  
 (A0IK 9/10)  
 139455  
 Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.

186/1999 F. Hoffmann-La Roche AG. Switzerland. “Substituted bisindolylmaleimide”  
 (C07D 403/14)  
 139456


Substituted pyrrole of formula



wherein R1 is hydrogen and R2 is methyl or R1 is methyl and R2 is hydrogen or R1 is hydroxymethyl and R2 is methyl as well as pharmaceutically acceptable prodrugs are antiproliferative agents useful in the treatment of cancer.

771/1999 Bayer  
Aktiengesellschaft.  
Germany. “Microcapsule composition containing spiroxamine”  
(A0IN 25/28) 139457

New microcapsule formulations of A) a particulate disperse phase of a) a reaction product of the isocyanate of the formula




if appropriate as a mixture with toluylene diisocyanate, and at least one diamine, polyamine, dialcohol, polyalcohol and/or aminoalcohol, b) at least one agrochemically active compound of a particular group of substances and, c) if appropriate, additives, and A) a liquid aqueous phase, and their use for applying the active compounds which they comprise.

981/1999 Syngenta  
Participations AG.  
Switzerland. “A pesticidal composition comprising neonicotinoid”  
(INT: CL, A0IN 43/56) 139458

The present invention provides an at least quaternary composition for controlling insects or representatives of the order acarina and microorganisms, which composition comprises; (A) an insecticidally effective amount of at least one neonicotinoid or phenylpyrazole insecticide, and (B) a fungicidally effective amount of at least three fungicides including: (B1) at least one phenylamide (acylalanine type), (B2) at least one phenylpyrrole and (B3) at least one triazole.

1022/1999 Pfizer Inc.  
USA. “Eletriptan hydrobromide monohydrate”  
(C07D 403/06 , A6IK 31/404) 139459

The present invention provides eletriptan hydrobromide monohydrate of the formula (I):



uses of, and compositions containing, said monohydrate.


489/2000 Almirall  
Prodesfarma, S.A.  
Spain.

“Indolyl piperidine compound”

(INT: CL, C07D 401/04)

139460

Indolylpiperidine compound of formula(I)



wherein:

A<sub>1</sub> represents an alkylene, alkyleneoxy, alkyleneithio, alkanoyl or hydroxyalkylene group; A<sub>2</sub> represents a single bond, an alkylene or alkenylene group; w represents a single bond or a phenylene or furanylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; R<sub>1</sub> represents a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl alkoxy-alkoxyalkyl, phenylalkyl group wherein the phenyl ring is unsubstituted or substituted by one or more halogen atoms or alkyl, alkoxy or arylalkoxy groups, or a cycloalkylalkyl group wherein the cycloalkyl group is unsubstituted or substituted by one or more halogen atoms, alkyl groups or alkoxy groups; R<sub>2</sub> represents a hydrogen or halogen atom or an alkyl or alkoxy group; and R<sub>3</sub> represents a carboxyl group or a tetrazolyl group;

890/2000 Bayer Corporation.  
USA.

“Polynucleotide peptide”

(INT: CL, C07K 5/10, A6IK 38/16)

139461

This invention provides novel, peptide that function in vivo to stimulate insulin release from pancreatic

beta cells in a glucose-dependent fashion. The insulin secretagogue peptide is shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptide of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP/PACAP-related polypeptide, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptide to said mammal.

74/2001 Warner-Lambert Company.  
USA.

“(S)-(+)-3-(aminomethyl)-5-methylhexanoic acid”  
(C07C 53/26)

139462


This invention relates to (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin). Pregabalin is useful for the treatment and prevention of seizure disorders, pain, and psychotic disorders. The invention also provides intermediates useful in the production of pregabalin.

565/2001 F.hoffmann-La Roche AG.  
Switzerland.

“Benzothiazole compound”  
(C07D 277/62)

139463

The present invention relates to compound of the general formula



for the treatment of diseases related to the adenosine receptor.

599/2001 Institute of Molecular Agrobiolgy,  
Singapore.

“A promoter that is cotton fibre-specific, comprising the promoter of the cotton active gene CFACT1”  
(C12 N 15/29)

139464

An isolated cotton fiber-specific promoter

comprising the 0.8 kb fragment of the promoter of the cotton B-tubulin gene CFTUB2 comprising the sequence of nucleotides 1 through 816 of SEQ ID NO: 2. The present invention relates to the cotton actin gene CFACT1, and the fiber-specific promoter thereof. These promoters show strong fiber-specific activity.

186/2002 Syngenta Limited.  
United Kingdom.

“An aqueous herbicidal composition comprising a salt of paraquat, a salt of diquat”

(A0IN 43/90)

139465

The use of an alginate as a pH-triggered gelling agent in the manufacture of a composition comprising a salt of paraquat, a salt of diquat or a mixture thereof, the composition further comprising an emetic and/or purgative such that a pH-triggered gel effect takes place at the acid pH of human gastric juice. The gelling agent is preferably used in the substantial absence of magnesium trisilicate and preferably has a 1% solution viscosity in water of from 2 to 2000 mPas.

445/2002 Warner-Lambert  
Company.  
USA.

“Liquid pharmaceutical composition comprising gamma-aminobutyric acid (GABA)”

(A6IK 31/197)

139466

A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.

27/2005


Pfizer Inc.  
USA.

“Sulfonamide substituted  $\beta$ -hydroxy-phenyl-ethyl-amine “

(C07C 311/08)

139467

The invention relates to compound of formula (1)



and to process for the preparation of, intermediate used in the preparation of, composition containing and the uses. The compound according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

313/2005

Zimmer AG  
Germany.

“Method for the manufacture of polyester or copolyester”

(C08G 63/78)

139468

The present invention relates to a method for manufacturing polyester or copolyester, in which the final reactor is controlled on the basis of the measurement of the temperature, a pressure differential, and the volume flow in the melt main flow.

946/2005

Recordati Ireland  
Limited.  
Ireland.

“A modified release pharmaceutical composition  
comprising lercanidipine”

(A6IK 31/4422)

139469

A modified release pharmaceutical composition comprises lercanidipine dissolved in a waxy substance comprising a polyalcohol fatty acid ester, the solution being contained within a pharmaceutically acceptable capsule. Preferably the polyalcohol fatty acid ester is a polyethylene glycol ester, a polypropylene glycol ester, a fatty acid glyceride or a mixture of two or more thereof. Most preferably, the polyalcohol fatty acid ester is a mixture of mono-, di- and triglycerides and polyethylene glycol mono- and diesters. Oral administration of the modified release pharmaceutical compositions to a patient has been shown to result in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for 24 hours after administration.

*~~~~~*

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488